ChiCTR2100053439 版本V1.8 版本创建时间2022/09/27 05:51:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053439 

最近更新日期:

Date of Last Refreshed on:

2022-05-26 10:10:42 

注册时间:

Date of Registration:

2021-11-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下腰方肌后路阻滞联合静脉自控镇痛对接受腹腔镜肾部分切除患者术后疼痛和早期恢复质量的影响

Public title:

Effects of ultrasound-guided posterior quadratus lumborum block combined with patient-controlled intravenous analgesia on postoperative pain and early recovery quality in patients undergoing laparoscopic partial nephrectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下腰方肌后路阻滞联合静脉自控镇痛对接受腹腔镜肾部分切除患者术后疼痛和早期恢复质量的影响

Scientific title:

Effects of ultrasound-guided posterior quadratus lumborum block combined with patient-controlled intravenous analgesia on postoperative pain and early recovery quality in patients undergoing laparoscopic partial nephrectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

秦上媛 

研究负责人:

柴军 

Applicant:

Qin Shangyuan 

Study leader:

Chai Jun 

申请注册联系人电话:

Applicant telephone:

+86 17612495728

研究负责人电话:

Study leader's telephone:

+86 18940259928

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinsy9531@163.com

研究负责人电子邮件:

Study leader's E-mail:

chaij@sj-hospital.org

申请单位网址(自愿提供):

Applicant website(voluntary supply):

中国医科大学附属盛京医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市和平区三好街36号

研究负责人通讯地址:

辽宁省沈阳市和平区三好街36号

Applicant address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

Study leader's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属盛京医院

Applicant's institution:

Shengjing Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属盛京医院

Affiliation of the Leader:

Shengjing Hospital of China Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021PS026K

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属盛京医院科研伦理委员会

Name of the ethic committee:

Ethics Committee of Shengjing Hospital of China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-11-15 00:00:00

伦理委员会联系人:

赵玉虹

Contact Name of the ethic committee:

Zhao Yuhong

伦理委员会联系地址:

辽宁省沈阳市和平区三好街36号

Contact Address of the ethic committee:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学附属盛京医院

Primary sponsor:

Shengjing Hospital of China Medical University

研究实施负责(组长)单位地址:

辽宁省沈阳市和平区三好街36号

Primary sponsor's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

中国医科大学附属盛京医院

具体地址:

和平区三好街36号

Institution
hospital:

Shengjing Hospital of China Medical University

Address:

36 Sanhao Street, Heping District

经费或物资来源:

辽宁省科研经费

Source(s) of funding:

Liaoning Province Scientific Research Funding

Target disease:

kidney cancer patients

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索后路腰方肌阻滞对接受腹腔镜肾部分切除术患者术后疼痛和早期康复质量的影响。  

Objectives of Study:

To explore the effect of posterior quadratus lumborum block on postoperative pain and early rehabilitation quality in patients undergoing laparoscopic partial nephrectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.择期行腹腔镜肾部分切除术的患者
2.ASA 分级Ⅰ~II级,性别不限,年龄18~65岁;
3..体重指数(BMI)<28kg/m2;

Inclusion criteria

1. Patients with elective laparoscopic partial nephrectomy
2. ASA classification I to II, no gender restriction, age 18 to 65 years old;
3. Body mass index (BMI) <28kg/m2;

排除标准:

1.有严重心脑血管疾病,如高血压3级、心绞痛、严重心律失常,严重心瓣膜疾病、脑梗塞等;
2.神经系统疾病或躯体感觉异常者;
3.有慢性疼痛病史以及长期服用镇痛药;
4.精神疾病,无法理解并合作的患者;
5.穿刺点附近皮肤感染者;
6.局麻药过敏史;
7.肾功能异常;
8.术中输血,术中使用地塞米松、甲泼尼龙等外源性激素类药物;
9.糖耐量异常或糖尿病;
10.肾上腺皮质功能亢进或减退;
11.手术时间>3h;

Exclusion criteria:

1. Severe cardiovascular and cerebrovascular diseases, such as grade 3 hypertension, angina pectoris, severe arrhythmia, severe heart valve disease, cerebral infarction, etc.;
2. Neurological diseases or somatosensory abnormalities;
3. History of chronic pain and long-term use of analgesics;
4. Mental illness, patients who cannot understand and cooperate;
5. Skin infection near the puncture point;
6. History of local anesthetic allergy.
7. Abnormal renal function;
8. Intraoperative blood transfusion, intraoperative use of exogenous hormone drugs such as dexamethasone and methylprednisolone;
9. Impaired glucose tolerance or diabetes;
10. Hyperfunction or hypofunction of adrenal cortex;
11. Operation time > 3h

研究实施时间:

Study execute time:

From 2021-11-22 00:00:00 To 2022-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-22 00:00:00 To 2022-05-31 00:00:00  

干预措施:

Interventions:

组别:

腰方肌阻滞复合病人自控性镇痛组

样本量:

30

Group:

Quadratus lumbosum block combined with patient-controlled analgesia group

Sample size:

干预措施:

腰方肌阻滞

干预措施代码:

Intervention:

quadratus lumbosum block

Intervention code:

组别:

单纯病人自控性镇痛组

样本量:

30

Group:

patient controlled analgesia group

Sample size:

干预措施:

空白对照

干预措施代码:

Intervention:

blank control

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China 

Province:

Liaoning 

City:

Shenyang 

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三级甲等 

Institution
hospital:

Shengjing Hospital of China Medical University

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

舒芬太尼用量

指标类型:

主要指标

Outcome:

Dosage of sufentanil

Type:

Primary indicator

测量时间点:

术后12h

测量方法:

Measure time point of outcome:

12h after surgery

Measure method:

指标中文名:

15项术后恢复质量量表评分

指标类型:

主要指标

Outcome:

15-item postoperative recovery quality scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

受试对象按照入组顺序编号为1-60,按照1:1的比率将其分为两组,区组长度设置为4。临床试验部门使用SPSS软件产生一段随机数字,从产生的随机数字中记录1-6的数字,按照上述随机数字排列区组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Subjects were numbered 1-60 according to the order of entry, divided into two groups according to the ratio of 1:1, and the block length was set to 4. The clinical trial department uses SPSS software to generate a random number, records the numbers 1-6 from the generated random numbers.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

两名麻醉师打开随机化信封,然后根据密封信封的随机分配方案,在单独的房间准备了一个 30 毫升的注射器,并将其交给进行神经阻滞的麻醉师。注射器装有 30 ml 0.375% 罗哌卡因或 30 ml 0.9% 等渗盐水。全程严格保证盲法,不得进行与试验药物相关的采访。所有注射器具有相同的外观。为了确保对麻醉师和受试者不知情,每个受试者都使用准备好的注射器中的药物进行超声引导的后路QLB。在整个研究过程中,进行神经阻滞的麻醉师、护理人员和外科医生对受试者的分配和治疗不知情。

Blinding:

Two anaesthetists opened the randomization envelope, then prepared a 30-mL syringe in a separate room and handed it over to the anaesthetist performing the nerve block according to the randomization protocol for the sealed envelope. The syringe contains 30 ml of 0.375% ropivacaine or 30 ml of 0.9% isotonic saline. The whole process is strictly guaranteed to be blinded, and no interviews related to the test drug are allowed. All syringes have the same appearance. To ensure anaesthetist and subject blindness, each subject underwent ultrasound-guided posterior quadratus lumborum block with medication in a prepared syringe. The anesthesiologists, paramedics, and surgeons who performed the nerve blocks were blinded to the assignment and treatment of subjects throughout the study.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年10月 以邮箱方式向研究者联系索取 (qinsy9531@163.com)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

In October 2022, contact the researcher by email(qinsy9531@163.com)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-21 12:09:01